Ramana Kuchibhatla

PRA Health Sciences, Inc. engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. It operates through Clinical Research and Data Solutions segment. The Clinical Research segment serves biopharmaceutical clients and offers outsourced clinical research and clinical trial related services. The Data Solutions segment involves in data and analytics; technology solutions and real-world insights, and services primarily to the company's life science clients. The company was founded in 1976 and is headquartered in Raleigh, NC.

Melior Pharmaceuticals I, Inc. is a mid-stage biopharmaceutical company that develops therapies for diabetes, Parkinson's disease, sleep disorders, and nonalcoholic steatohepatitis (NASH). The private company is based in Exton, PA and was founded in 2008 by Andrew Reaume. The company's lead clinical stage candidates are in the areas of diabetes, NASH, Parkinson's disease, and sleep disorders. The company leverages the technology of their affiliate discovery for stage 1 research. Tolimidone is a Lyn kinase activator for treating type 2 diabetes and NASH. Mesocarb is a dopamine reuptake inhibitor for treating Parkinson's disease, sleep disorders, and other CNS conditions.

Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.